Abstract
Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most common of which is Alzheimer's disease. Environmental causes of tauopathies include repetitive head trauma associated with some sports. To identify common genetic variation contributing to risk for tauopathies, we carried out a genome-wide association study of 1,114 individuals with PSP (cases) and 3,247 controls (stage 1) followed by a second stage in which we genotyped 1,051 cases and 3,560 controls for the stage 1 SNPs that yielded P ≤ 10-3. We found significant previously unidentified signals (P < 5 × 10-8) associated with PSP risk at STX6, EIF2AK3 and MOBP. We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression. The genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface, for the endoplasmic reticulum unfolded protein response and for a myelin structural component.
Original language | English |
---|---|
Pages (from-to) | 699-705 |
Number of pages | 7 |
Journal | Nature Genetics |
Volume | 43 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2011 |
Externally published | Yes |
Fingerprint
Dive into the research topics of 'Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature Genetics, Vol. 43, No. 7, 07.2011, p. 699-705.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy
AU - Höglinger, Günter U.
AU - Melhem, Nadine M.
AU - Dickson, Dennis W.
AU - Sleiman, Patrick M.A.
AU - Wang, Li San
AU - Klei, Lambertus
AU - Rademakers, Rosa
AU - De Silva, Rohan
AU - Litvan, Irene
AU - Riley, David E.
AU - Van Swieten, John C.
AU - Heutink, Peter
AU - Wszolek, Zbigniew K.
AU - Uitti, Ryan J.
AU - Vandrovcova, Jana
AU - Hurtig, Howard I.
AU - Gross, Rachel G.
AU - Maetzler, Walter
AU - Goldwurm, Stefano
AU - Tolosa, Eduardo
AU - Borroni, Barbara
AU - Pastor, Pau
AU - Cantwell, Laura B.
AU - Han, Mi Ryung
AU - Dillman, Allissa
AU - Van Der Brug, Marcel P.
AU - Gibbs, J. Raphael
AU - Cookson, Mark R.
AU - Hernandez, Dena G.
AU - Singleton, Andrew B.
AU - Farrer, Matthew J.
AU - Yu, Chang En
AU - Golbe, Lawrence I.
AU - Revesz, Tamas
AU - Hardy, John
AU - Lees, Andrew J.
AU - Devlin, Bernie
AU - Hakonarson, Hakon
AU - Müller, Ulrich
AU - Schellenberg, Gerard D.
AU - Albin, Roger L.
AU - Alonso, Elena
AU - Antonini, Angelo
AU - Apfelbacher, Manuela
AU - Arnold, Steven E.
AU - Avila, Jesus
AU - Beach, Thomas G.
AU - Beecher, Sherry
AU - Berg, Daniela
AU - Bird, Thomas D.
AU - Bogdanovic, Nenad
AU - Boon, Agnita J.W.
AU - Bordelon, Yvette
AU - Brice, Alexis
AU - Budka, Herbert
AU - Canesi, Margherita
AU - Chiu, Wang Zheng
AU - Cilia, Roberto
AU - Colosimo, Carlo
AU - De Deyn, Peter P.
AU - De Yebenes, Justo Garcãa
AU - Kaat, Laura Donker
AU - Duara, Ranjan
AU - Durr, Alexandra
AU - Engelborghs, Sebastiaan
AU - Fabbrini, Giovanni
AU - Finch, Nicole A.
AU - Flook, Robyn
AU - Frosch, Matthew P.
AU - Gaig, Carles
AU - Galasko, Douglas R.
AU - Gasser, Thomas
AU - Gearing, Marla
AU - Geller, Evan T.
AU - Ghetti, Bernardino
AU - Graff-Radford, Neill R.
AU - Grossman, Murray
AU - Hall, Deborah A.
AU - Hazrati, Lili Naz
AU - Höllerhage, Matthias
AU - Jankovic, Joseph
AU - Juncos, Jorge L.
AU - Karydas, Anna
AU - Kretzschmar, Hans A.
AU - Leber, Isabelle
AU - Lee, Virginia M.
AU - Lieberman, Andrew P.
AU - Lyons, Kelly E.
AU - Mariani, Claudio
AU - Masliah, Eliezer
AU - Massey, Luke A.
AU - McLean, Catriona A.
AU - Meucci, Nicoletta
AU - Miller, Bruce L.
AU - Mollenhauer, Brit
AU - Möller, Jens C.
AU - Morris, Huw R.
AU - Morris, Chris
AU - O'Sullivan, Sean S.
AU - Oertel, Wolfgang H.
AU - Ottaviani, Donatella
AU - Padovani, Alessandro
AU - Pahwa, Rajesh
AU - Pezzoli, Gianni
AU - Pickering-Brown, Stuart
AU - Poewe, Werner
AU - Rabano, Alberto
AU - Rajput, Alex
AU - Reich, Stephen G.
AU - Respondek, Gesine
AU - Roeber, Sigrun
AU - Rohrer, Jonathan D.
AU - Ross, Owen A.
AU - Rossor, Martin N.
AU - Sacilotto, Giorgio
AU - Seeley, William W.
AU - Seppi, Klaus
AU - Silveira-Moriyama, Laura
AU - Spina, Salvatore
AU - Srulijes, Karin
AU - St. George-Hyslop, Peter
AU - Stamelou, Maria
AU - Standaert, David G.
AU - Tesei, Silvana
AU - Tourtellotte, Wallace W.
AU - Trenkwalder, Claudia
AU - Troakes, Claire
AU - Trojanowski, John Q.
AU - Troncoso, Juan C.
AU - Van Deerlin, Vivianna M.
AU - Vonsattel, Jean Paul G.
AU - Wenning, Gregor K.
AU - White, Charles L.
AU - Winter, Pia
AU - Zarow, Chris
AU - Zecchinelli, Anna L.
N1 - Funding Information: The datasets used for older controls were obtained from Database for Genotypes and Phenotypes (dbGap) at http://www.ncbi.nlm.nih.gov/gap/. Funding support for the ‘Genetic Consortium for Late Onset Alzheimer’s Disease’ was provided through the Division of Neuroscience, NIA. The Genetic Consortium for Late Onset Alzheimer’s Disease (study accession number: phs000168.v1.p1) includes a genomewide association study funded as part of the Division of Neuroscience, NIA. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by Genetic Consortium for Late Onset Alzheimer’s Disease. Funding support for the ‘CIDR Visceral Adiposity Study’ (study accession number: phs000169.v1.p1) was provided through the Division of Aging Biology and the Division of Geriatrics and Clinical Gerontology, NIA. The CIDR Visceral Adiposity Study includes a genomewide association study funded as part of the Division of Aging Biology and the Division of Geriatrics and Clinical Gerontology, NIA. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by Heath ABC Study Investigators. Funding support for the Personalized Medicine Research Project (PMRP) was provided through a cooperative agreement (U01HG004608) with the National Human Genome Research Institute (NHGRI), with additional funding from the National Institute for General Medical Sciences Funding Information: We thank the subjects and their families that participated in this study. This work was funded by grants from the CurePSP Foundation, the Peebler PSP Research Foundation and US National Institutes of Health (NIH) grants R37 AG 11762, R01 PAS03092, P50 NS72187, P01 AG17216 (National Institute on Aging (NIA)/NIH), MH057881 and MH077930 (National Institute of Mental Health (NIMH)). Work was also supported in part by the NIA Intramural Research Program, the German National Genome Research Network (01GS081364) and the Deutsche Forschungsgemeinschaft (HO 2402/61), Prinses Beatrix Fonds (JCvS, 010128), the Reta Lila Weston Trust and the UK Medical Research Council (RdS: G0501560). The Newcastle Brain Tissue Resource provided tissue and is funded in part by a grant from the UK Medical Research Council (G0400074), by the Newcastle National Institute for Health Research (NIHR) Biomedical Research Centre in Ageing and Age Related Diseases to the Newcastle upon Tyne Hospitals National Health Service Foundation Trust and by a grant from the Alzheimer’s Society and Alzheimer’s Research Trust as part of the Brains for Dementia Research Project. We acknowledge the contribution of many tissue samples from the Harvard Brain Tissue Resource Center. We also acknowledge the ‘Human Genetic Bank of Patients affected by Parkinson Disease and Parkinsonism’ (http://www. parkinson.it/dnabank.html) of the Telethon Genetic Biobank Network, supported by TELETHON Italy (project no. GTB07001) and by Fondazione Grigioni per il Morbo di Parkinson. The University of Toronto sample collection was supported by grants from Wellcome Trust, Howard Hughes Medical Institute and the Canadian Institute of Health Research. BrainNetGermany is supported by the Federal Ministry of Education and Research (BMBF) (01GI0505). R.d.S., A.J.L. and J.A.H. are funded by the Reta Lila Weston Trust and the PSP (Europe) Association. R.d.S. is funded by the UK Medical Research Council (Grant G0501560) and Cure PSP+. Z.K.W. is partially supported by the NIH/NINDS 1RC2NS070276, NS057567, P50NS072187, Mayo Clinic Florida (MCF) Research Committee CR programs (MCF #90052030 and MCF #90052030) and the gift from C.E. Bolch Jr. and S.B. Bolch (MCF #90052031/PAU #90052). The Mayo Clinic College of Medicine would like to acknowledge M. Baker, R. Crook, M. DeJesusHernandez and N. Rutherford for their preparation of samples. P.P. was supported by a grant from the Government of Navarra (‘Ayudas para la Realización de Proyectos de Investigación’ 2006–2007) and acknowledges the ‘Iberian Atypical Parkinsonism Study Group Researchers’: M.A. Pastor, M.R. Luquin, M. Riverol, J.A. Obeso and M.C. RodriguezOroz (Department of Neurology, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain), M. Blazquez (Neurology Department, Hospital Universitario Central de Asturias, Oviedo, Spain), A. Lopez de Munain, B. Indakoetxea, J. Olaskoaga, J. Ruiz, J. Félix Martí Massó (Servicio de Neurología, Hospital Donostia, San Sebastián, Spain), V. Alvarez (Genetics Department, Hospital Universitario Central de Asturias, Oviedo, Spain), T. Tuñon (Banco de Tejidos Neurologicos, CIBERNED, Hospital de Navarra, Navarra, Spain), F. Moreno (Servicio de Neurología, Hospital Ntra. Sra. de la Antigua, Zumarraga, Gipuzkoa, Spain), A. Alzualde (Neurogenétics Department, Hospital Donostia, San Sebastián, Spain). E.T. wishes to acknowledge the Banco de Tejidos Neurológicos de la Universidad de BarcelonaHospital Clinic, which provided many tissue samples for the project. We also acknowledge E. Loomis for providing technical support. Funding Information: (NIGMS). The samples used for PMRP analyses were obtained with funding from Marshfield Clinic, Health Resources Service Administration Office of Rural Health Policy grant number D1A RH00025 and Wisconsin Department of Commerce Technology Development Fund contract number TDF FYO10718. Funding support for genotyping, which was performed at Johns Hopkins University, was provided by the NIH (U01HG004438). Assistance with phenotype harmonization and genotype cleaning was provided by the eMERGE Administrative Coordinating Center (U01HG004603) and the National Center for Biotechnology Information (NCBI). The datasets used for the analyses described in this manuscript were obtained from dbGaP at http://www.ncbi.nlm.nih.gov/gap through dbGaP accession number phs000170.v1.p1.
PY - 2011/7
Y1 - 2011/7
N2 - Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most common of which is Alzheimer's disease. Environmental causes of tauopathies include repetitive head trauma associated with some sports. To identify common genetic variation contributing to risk for tauopathies, we carried out a genome-wide association study of 1,114 individuals with PSP (cases) and 3,247 controls (stage 1) followed by a second stage in which we genotyped 1,051 cases and 3,560 controls for the stage 1 SNPs that yielded P ≤ 10-3. We found significant previously unidentified signals (P < 5 × 10-8) associated with PSP risk at STX6, EIF2AK3 and MOBP. We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression. The genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface, for the endoplasmic reticulum unfolded protein response and for a myelin structural component.
AB - Progressive supranuclear palsy (PSP) is a movement disorder with prominent tau neuropathology. Brain diseases with abnormal tau deposits are called tauopathies, the most common of which is Alzheimer's disease. Environmental causes of tauopathies include repetitive head trauma associated with some sports. To identify common genetic variation contributing to risk for tauopathies, we carried out a genome-wide association study of 1,114 individuals with PSP (cases) and 3,247 controls (stage 1) followed by a second stage in which we genotyped 1,051 cases and 3,560 controls for the stage 1 SNPs that yielded P ≤ 10-3. We found significant previously unidentified signals (P < 5 × 10-8) associated with PSP risk at STX6, EIF2AK3 and MOBP. We confirmed two independent variants in MAPT affecting risk for PSP, one of which influences MAPT brain expression. The genes implicated encode proteins for vesicle-membrane fusion at the Golgi-endosomal interface, for the endoplasmic reticulum unfolded protein response and for a myelin structural component.
UR - http://www.scopus.com/inward/record.url?scp=79959689333&partnerID=8YFLogxK
U2 - 10.1038/ng.859
DO - 10.1038/ng.859
M3 - Article
AN - SCOPUS:79959689333
SN - 1061-4036
VL - 43
SP - 699
EP - 705
JO - Nature Genetics
JF - Nature Genetics
IS - 7
ER -